{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:01:04Z","timestamp":1781535664005,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10875-020-00888-2","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T23:08:10Z","timestamp":1602889690000},"page":"89-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2933-814X","authenticated-orcid":false,"given":"Sharat","family":"Chandra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmuganathan","family":"Chandrakasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blachy J.","family":"D\u00e1vila Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack J.","family":"Bleesing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish R.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Grimley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Krupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"issue":"12","key":"888_CR1","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"888_CR2","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1182\/blood.V83.4.1149.1149","volume":"83","author":"A Fischer","year":"1994","unstructured":"Fischer A, Landais P, Friedrich W, Gerritsen B, Fasth A, Porta F, et al. Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodeficiency. Blood. 1994;83(4):1149\u201354.","journal-title":"Blood."},{"issue":"9357","key":"888_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0140-6736(03)12513-5","volume":"361","author":"C Antoine","year":"2003","unstructured":"Antoine C, M\u00fcller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003;361(9357):553\u201360.","journal-title":"Lancet."},{"issue":"3","key":"888_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/eci.12.9","volume":"8","author":"R Chiesa","year":"2012","unstructured":"Chiesa R, Veys P. Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies. Expert Rev Clin Immunol. 2012;8(3):255\u201366 quiz 67.","journal-title":"Expert Rev Clin Immunol"},{"issue":"13","key":"888_CR5","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1182\/blood-2018-01-828277","volume":"132","author":"CE Allen","year":"2018","unstructured":"Allen CE, Marsh R, Dawson P, Bollard CM, Shenoy S, Roehrs P, et al. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood. 2018;132(13):1438\u201351.","journal-title":"Blood."},{"issue":"26","key":"888_CR6","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1182\/blood-2010-04-282392","volume":"116","author":"RA Marsh","year":"2010","unstructured":"Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116(26):5824\u201331.","journal-title":"Blood."},{"issue":"8","key":"888_CR7","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.bbmt.2015.04.009","volume":"21","author":"RA Marsh","year":"2015","unstructured":"Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, et al. Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transplant. 2015;21(8):1460\u201370.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"888_CR8","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jaci.2016.01.053","volume":"138","author":"K Rao","year":"2016","unstructured":"Rao K, Adams S, Qasim W, Allwood Z, Worth A, Silva J, et al. Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen. J Allergy Clin Immunol. 2016;138(4):1152\u201360.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"888_CR9","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","volume":"118","author":"D Moratto","year":"2011","unstructured":"Moratto D, Giliani S, Bonfim C, Mazzolari E, Fischer A, Ochs HD, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood. 2011;118(6):1675\u201384.","journal-title":"Blood."},{"issue":"3","key":"888_CR10","doi-asserted-by":"publisher","first-page":"S406","DOI":"10.1016\/j.bbmt.2017.12.519","volume":"24","author":"S Chandra","year":"2018","unstructured":"Chandra S, Bleesing JJ, Jordan MB, Grimley MS, Khandelwal P, Davies SM, et al. Post-transplant CD34+selected stem cell \u201cboost\u201d as intervention for mixed chimerism following reduced intensity conditioning HSCT in children and young adults with primary immune deficiencies. Biology of Blood and Marrow Transplant. 2018;24(3):S406\u2013S7.","journal-title":"Biology of Blood and Marrow Transplant"},{"issue":"6","key":"888_CR11","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jaci.2018.12.1010","volume":"143","author":"F Ferrua","year":"2019","unstructured":"Ferrua F, Galimberti S, Courteille V, Slatter MA, Booth C, Moshous D, et al. Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT\/ESID-IEWP-SCETIDE-PIDTC study. J Allergy Clin Immunol. 2019;143(6):2238\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"9915","key":"888_CR12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","volume":"383","author":"T G\u00fcng\u00f6r","year":"2014","unstructured":"G\u00fcng\u00f6r T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436\u201348.","journal-title":"Lancet."},{"issue":"4","key":"888_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295\u2013304.","journal-title":"Transplantation."},{"issue":"6","key":"888_CR14","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","volume":"21","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984\u201399.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"888_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood-2004-03-0960","volume":"105","author":"K Rao","year":"2005","unstructured":"Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 2005;105(2):879\u201385.","journal-title":"Blood."},{"key":"888_CR16","doi-asserted-by":"crossref","unstructured":"Contreras CF, Long-Boyle JR, Shimano KA, Melton A, Kharbanda S, Dara J, et al. Reduced toxicity conditioning for nonmalignant hematopoietic cell transplants. Biol Blood Marrow Transplant. 2020.","DOI":"10.1016\/j.bbmt.2020.06.004"},{"issue":"3","key":"888_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbmt.2017.11.009","volume":"24","author":"MA Slatter","year":"2018","unstructured":"Slatter MA, Rao K, Abd Hamid IJ, Nademi Z, Chiesa R, Elfeky R, et al. Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience. Biol Blood Marrow Transplant. 2018;24(3):529\u201336.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"888_CR18","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","volume":"96","author":"PD Kottaridis","year":"2000","unstructured":"Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96(7):2419\u201325.","journal-title":"Blood."},{"issue":"5","key":"888_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.bbmt.2017.02.007","volume":"23","author":"K Green","year":"2017","unstructured":"Green K, Pearce K, Sellar RS, Jardine L, Nicolson PLR, Nagra S, et al. Impact of alemtuzumab scheduling on graft-versus-host disease after unrelated donor fludarabine and melphalan allografts. Biol Blood Marrow Transplant. 2017;23(5):805\u201312.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"888_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/ejh.13085","volume":"101","author":"M Robin","year":"2018","unstructured":"Robin M, Raj K, Chevret S, Gauthier J, de Lavallade H, Michonneau D, et al. Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning. Eur J Haematol. 2018;101(4):466\u201374.","journal-title":"Eur J Haematol"},{"issue":"7","key":"888_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10875-019-00659-8","volume":"39","author":"RA Marsh","year":"2019","unstructured":"Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, et al. Chronic granulomatous disease-associated IBD resolves and does not adversely impact survival following allogeneic HCT. J Clin Immunol. 2019;39(7):653\u201367.","journal-title":"J Clin Immunol"},{"issue":"9","key":"888_CR22","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1182\/bloodadvances.2020001748","volume":"4","author":"M Felber","year":"2020","unstructured":"Felber M, Steward CG, Kentouche K, Fasth A, Wynn RF, Zeilhofer U, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. Blood Adv. 2020;4(9):1998\u20132010.","journal-title":"Blood Adv"},{"issue":"23","key":"888_CR23","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood.2019002939","volume":"135","author":"LM Burroughs","year":"2020","unstructured":"Burroughs LM, Petrovic A, Brazauskas R, Liu X, Griffith LM, Ochs HD. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood. 2020;135(23):2094\u2013105.","journal-title":"Blood."}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-020-00888-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-020-00888-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-020-00888-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T11:40:53Z","timestamp":1634384453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-020-00888-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1007\/s10875-020-00888-2","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}